Skip to Main Content


Skip Nav Destination

Acute Leukemias

November 5, 2021

A collection of features and news articles published in ASH Clinical News related to acute leukemias.


IDH Inhibitor Olutasidenib Active With or Without Azacitidine in IDH1-Mutated AML

Treatment with olutasidenib led to durable remission and mutation clearance in patients with relapsed or refractory (R/R) IDH1-mutated acute myeloid leukemia (AML) with or without azacitidine ...

Addition of Daratumumab to Standard Therapy Does Not Increase Cardiac Events in AL Amyloidosis

Across all cardiac stages (I-IIA), patients with newly diagnosed light chain (AL) amyloidosis treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone (D-VCd) had better outcomes than those treated with VCd ...

Small Percentage of aPL-Positive Patients Without Autoimmune Diseases Received Immunosuppression

About 15% of patients with persistently positive antiphospholipid antibodies (aPLs) without other systemic autoimmune disease were found to have received immunosuppression other than corticosteroids or hydroxychloroquine for certain aPL manifestations ...

Dasatinib/Prednisone Induction Followed by Blinatumomab/Dasatinib May Be an Alternative to Transplant in Ph+ ALL

Use of the anti-CD19 bispecific T-cell engaging antibody blinatumomab given in conjunction with the tyrosine kinase inhibitor (TKI) dasatinib may provide an alternative to allogenic transplant for older adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia ...

Imperative of CR Achievement Before Transplant May Not Be Best Approach in AML

Select patients with acute myeloid leukemia (AML) who have a poor response to induction therapy or have relapsed disease may benefit from going directly to allogeneic hematopoietic cell transplantation (alloHCT) when a stem cell donor is readily available ...

Reduced Venetoclax Exposure With Azacitidine Appears Feasible in Treatment-Naïve AML

Limiting venetoclax (VEN) exposure to the concurrent days of azacitidine (AZA) administration was associated with response rates comparable to the recommended venetoclax administration period of 28 days in treatment-naïve patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy ...

Co-mutation Patterns Allowed for Updated Risk Stratification of NPM1-Mutated AML

Many patients with NPM1-mutated acute myeloid leukemia (AML) carry at least three gene mutations, and consideration of these co-mutational patterns is necessary for accurate risk stratification ...

Ivosidenib/Azacitidine Combo Improved Overall Survival in IDH1-Mutated AML

The combination of the IDH1 inhibitor ivosidenib and azacitidine demonstrated significant clinical benefit in patients with newly diagnosed IDH1-mutated acute myeloid leukemia...

Code Status Transition in High-Risk AML Happening Near End of Life

Patients with high-risk acute myeloid leukemia (AML) often had code change status transitions occur very near the end of life...

Azacitidine and Decitabine Garner Comparable Clinical Outcomes Among Older, Unfit Patients With AML

Treatment responses and survival outcomes were comparable among older, unfit patients with acute myeloid leukemia (AML) who received either of two hypomethylating agents (HMAs), azacitidine or decitabine...




Connect with us:

September 2023


Close Modal

or Create an Account

Close Modal
Close Modal